PathAI, GSK partner to accelerate research, drug development

By The Science Advisory Board staff writers

April 5, 2022 -- PathAI and GlaxoSmithKline (GSK) have announced a strategic multiyear partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH).

Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.

The companies said that the partnership will combine GSK's and PathAI's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be integrated into clinical trials.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.